北京破解创新药入院“最后一公里”难题：医院采购无需层层审批

Core Points - Beijing has implemented measures to facilitate the entry of innovative drugs and medical devices into hospitals, addressing procurement bottlenecks and expediting clinical application processes [1][2] Group 1: Policy Measures - Hospitals in Beijing can directly include national medical insurance negotiated drugs and Class I innovative drugs in their procurement lists without holding selection meetings [1] - A green channel has been established for clinically urgent or significantly effective innovative drugs and devices, ensuring priority support [2] - The Beijing Municipal Health Commission has introduced initiatives to support the entry of innovative drugs and devices into municipal hospitals, aiming to resolve procurement issues [1] Group 2: Collaboration and Clinical Research - The "pairing project" has been implemented to foster collaboration between renowned companies and hospitals, resulting in strategic agreements between major pharmaceutical firms and key hospitals [2] - Significant progress has been made in clinical research and academic exchanges, with multiple clinical trials initiated and new treatment protocols established [3] - Specific collaborations include the establishment of a one-stop service platform for clinical trials at Anzhen Hospital and the initiation of 14 clinical trials at Peking University Cancer Hospital in partnership with AstraZeneca [3]